okay, here’s a draft article ‌based ⁢on the⁢ provided text, expanded with ⁤the requested elements, aiming for E-E-A-T, Google news ⁣friendliness, and the specific structural ⁣requirements. It’s a ample piece, designed ‍to be a thorough resource. I’ve included placeholders for images/videos where appropriate. Please read the “Critically ⁤important Considerations” section at the end before publishing.

Prasugrel Outperforms Ticagrelor in Diabetic patients Post-Stent Implantation: ⁢TUXEDO-2 Trial Findings

New Orleans,LA – November 10,2025 ‍ – A new study presented at ⁣the American Heart Association’s Scientific Sessions 2025⁤ challenges conventional‍ wisdom regarding antiplatelet therapy following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in patients ​with diabetes. The TUXEDO-2 trial reveals that prasugrel may be a superior choice to ticagrelor in⁣ preventing adverse cardiovascular events and bleeding complications in individuals with type 1 or type 2 diabetes. This finding is notable, as both drugs ‌are commonly‌ prescribed to prevent blood clots from forming in stents.

The ⁤Problem: Stent Thrombosis and⁢ the Need for Dual‌ Antiplatelet Therapy

Coronary artery disease (CAD) remains a leading cause of death worldwide. PCI, often ⁢involving the placement of a drug-eluting stent, is a common and effective treatment⁣ for blocked arteries. However, stents aren’t a ‘cure-all’.A major risk following stent implantation is stent thrombosis – the formation of a blood clot within the stent⁣ – which can lead to‍ heart attack or stroke.

to mitigate this risk, patients are prescribed dual antiplatelet therapy (DAPT), typically consisting of aspirin plus a P2Y12 inhibitor.Ticagrelor⁢ and prasugrel are two commonly used P2Y12 inhibitors. They work by preventing platelets from clumping‌ together and forming clots. The choice between ⁢the two‍ has ​historically been guided by ‌factors‍ like bleeding risk and individual patient characteristics, but​ frequently enough with the assumption of comparable efficacy.

(Image: Illustration of a drug-eluting stent in an artery)

TUXEDO-2: Study Design and population

The TUXEDO-2 ⁣study was a randomized, ⁣controlled clinical trial involving 1,800 adults in⁣ India diagnosed with type 1 or type 2 diabetes and multivessel disease (blockages in multiple coronary arteries). ⁤ Participants underwent PCI⁢ with a drug-eluting stent. ⁤ Crucially, ‌all​ patients received ​one⁤ of two specific DES types: either the⁢ BioMatrix ​or the Onyx stent.

After the procedure, patients were randomly assigned to receive either:

* ⁣ Prasugrel (10mg daily) plus aspirin
* ⁤ ⁢ Ticagrelor (90mg twice daily)​ plus aspirin

The primary outcome measured was a composite of heart attack, stroke, bleeding complications (defined by standardized criteria), and death, assessed after one year‍ of treatment. Researchers also analyzed individual components of this composite outcome.